<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37537705</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000901</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000901</ELocationID><Abstract><AbstractText>Drug development in lupus has improved over the past 10 years but still lags behind that of other rheumatic disease areas. Assessment of prospective lupus therapies in clinical trials has proved challenging for reasons that are multifactorial including the heterogeneity of the disease, study design limitations and a lack of validated biomarkers which greatly impacts regulatory decision-making. Moreover, most composite outcome measures currently used in trials do not include patient-reported outcomes. Given these factors, the Addressing Lupus Pillars for Health Advancement Global Advisory Committee members who serve on the drug development team identified an opportunity to convene a meeting to facilitate information sharing on completed and existing outcome measure development efforts. This meeting report highlights information presented during the meeting as well as a discussion on how the lupus community may work together with regulatory agencies to simplify and standardise outcome measures to accelerate development of lupus therapeutics.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buie</LastName><ForeName>Joy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4026-4812</Identifier><AffiliationInfo><Affiliation>Research, Lupus Foundation of America, Washington, District of Columbia, USA buie@lupus.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Health Policy and Regulatory Affairs, Faegre Drinker Biddle and Reath LLP Washington, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morand</LastName><ForeName>Eric F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0002-9507-3338</Identifier><AffiliationInfo><Affiliation>Rheumatology, Monash Medical Centre, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vollenhoven</LastName><ForeName>Ronald F</ForeName><Initials>RF</Initials><Identifier Source="ORCID">0000-0001-6438-8663</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werth</LastName><ForeName>Victoria P</ForeName><Initials>VP</Initials><Identifier Source="ORCID">0000-0003-3030-5369</Identifier><AffiliationInfo><Affiliation>Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touma</LastName><ForeName>Zahi</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5177-2076</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipsky</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>RILITE Research Institute, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalunian</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, UCSD, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askanase</LastName><ForeName>Anca D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-4597-5023</Identifier><AffiliationInfo><Affiliation>Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ines</LastName><ForeName>L</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3172-3570</Identifier><AffiliationInfo><Affiliation>Faculty of Health Sciences, Univ Beira Interior, Covilha, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Reed Consulting, LLC, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>MaryBeth</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7394-2862</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franson</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faegre Drinker Consulting, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costenbader</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schanberg</LastName><ForeName>Laura Eve</ForeName><Initials>LE</Initials><Identifier Source="ORCID">0000-0002-1913-6472</Identifier><AffiliationInfo><Affiliation>Pediatrics, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">outcome assessment, health care</Keyword></KeywordList><CoiStatement>Competing interests: KC&#x2019;s disclosures are as follows: editing/authoring/publishing: American College of Rheumatology; Elsevier, Inc.; UpToDate (Wolters Kluwer Health, Inc.); consulting/advising: Amgen, Inc.; AstraZeneca; GlaxoSmithKline; Hospital for Special Surgery; Neutrolis; faculty/instructing/speaking/lecturing: Harvard T. H. Chan School of Public Health; New York University&#x2014;NYU Langone Hospitals; financial interest (&lt;1%): Alkermes, PLC; governmental review process: National Institutes of Health; scientific advisory board: Lupus Foundation of America. All of KC&#x2019;s financial interests were &lt;US$5000 for 2022.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37537705</ArticleId><ArticleId IdType="pmc">PMC9930541</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000901</ArticleId><ArticleId IdType="pii">10/1/e000901</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manzi S, Raymond S, Tse K, et al. . Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Sci Med 2019;6:e000342. 10.1136/lupus-2019-000342</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000342</ArticleId><ArticleId IdType="pmc">PMC6667778</ArticleId><ArticleId IdType="pubmed">31413854</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov 2019;18:495&#x2013;6. 10.1038/d41573-019-00074-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-019-00074-z</ArticleId><ArticleId IdType="pubmed">31267067</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison RK. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov 2016;15:817&#x2013;8. 10.1038/nrd.2016.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.184</ArticleId><ArticleId IdType="pubmed">27811931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse K, Sangodkar S, Bloch L, et al. . The ALPHA project: establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Sci Med 2021;8:e000433. 10.1136/lupus-2020-000433</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000433</ArticleId><ArticleId IdType="pmc">PMC7875256</ArticleId><ArticleId IdType="pubmed">33563729</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R, Voskuyl A, Bertsias G, et al. . A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554&#x2013;61. 10.1136/annrheumdis-2016-209519</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209519</ArticleId><ArticleId IdType="pubmed">27884822</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Bertsias G, Doria A, et al. . 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021;8:e000538. 10.1136/lupus-2021-000538</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId><ArticleId IdType="pmc">PMC8614136</ArticleId><ArticleId IdType="pubmed">34819388</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamowicz M, Abrahamowicz MI, Lipsky PE. External validation of the lupus multivariable outcome score for systemic lupus erythematosus trials. ACR Open Rheumatol 2022;4:923&#x2013;30. 10.1002/acr2.11451</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11451</ArticleId><ArticleId IdType="pmc">PMC9555192</ArticleId><ArticleId IdType="pubmed">35962577</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht J, Taylor L, Berlin JA, et al. . The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889&#x2013;94. 10.1111/j.0022-202X.2005.23889.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23889.x</ArticleId><ArticleId IdType="pmc">PMC3928016</ArticleId><ArticleId IdType="pubmed">16297185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D, Zamalin D, Chakka S, et al. . Cutaneous lupus concerns from the patient perspective: a qualitative study. Lupus Sci Med 2021;8:e000444. 10.1136/lupus-2020-000444</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000444</ArticleId><ArticleId IdType="pmc">PMC8404455</ArticleId><ArticleId IdType="pubmed">34452954</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakka S, Krain RL, Ahmed S, et al. . Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol 2021;84:1562&#x2013;7. 10.1016/j.jaad.2020.07.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.07.047</ArticleId><ArticleId IdType="pmc">PMC8106875</ArticleId><ArticleId IdType="pubmed">32682879</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Werth VP, Merola JF, et al. . Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest 2019;129:1359&#x2013;71. 10.1172/JCI124466</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124466</ArticleId><ArticleId IdType="pmc">PMC6391094</ArticleId><ArticleId IdType="pubmed">30645203</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al. . The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008;144:173&#x2013;80. 10.1001/archderm.144.2.173</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.144.2.173</ArticleId><ArticleId IdType="pmc">PMC2829653</ArticleId><ArticleId IdType="pubmed">18283174</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Moghadam-Kia S, LoMonico J, et al. . Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203&#x2013;8. 10.1001/archdermatol.2010.435</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2010.435</ArticleId><ArticleId IdType="pmc">PMC3282059</ArticleId><ArticleId IdType="pubmed">21339447</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth VP, Furie RA, Romero-Diaz J, et al. . Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med 2022;387:321&#x2013;31. 10.1056/NEJMoa2118024</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118024</ArticleId><ArticleId IdType="pubmed">35939578</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376&#x2013;86. 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase AD, Nguyen SC, Costenbader K, et al. . Comparison of the Lupus Foundation of America-rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical investigators or real-world clinicians. Arthritis Care Res (Hoboken) 2018;70:1058&#x2013;63. 10.1002/acr.23445</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23445</ArticleId><ArticleId IdType="pubmed">28992399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Gamboa-Cardenas RV, Re&#xe1;tegui-Sokolova C, et al. . Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Sci Med 2020;7:e000419. 10.1136/lupus-2020-000419</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000419</ArticleId><ArticleId IdType="pmc">PMC7552838</ArticleId><ArticleId IdType="pubmed">33046557</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Hoi AY-B, et al. . Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther 2017;19:62. 10.1186/s13075-017-1256-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1256-6</ArticleId><ArticleId IdType="pmc">PMC5359963</ArticleId><ArticleId IdType="pubmed">28320433</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Huq M, et al. . Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet Rheumatology 2019;1:e95&#x2013;102. 10.1016/S2665-9913(19)30037-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30037-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Oon S, Huq M, Golder V, et al. . Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis 2019;78:629&#x2013;33. 10.1136/annrheumdis-2018-214427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214427</ArticleId><ArticleId IdType="pubmed">30679152</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Trasieva T, Berglind A, et al. . Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of anifrolumab. Ann Rheum Dis 2018;77:706&#x2013;13. 10.1136/annrheumdis-2017-212504</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212504</ArticleId><ArticleId IdType="pmc">PMC5909750</ArticleId><ArticleId IdType="pubmed">29420200</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Isenberg DA, Wallace DJ, et al. . Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2B address II study. Rheumatology (Oxford) 2020;59:2930&#x2013;8. 10.1093/rheumatology/keaa029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa029</ArticleId><ArticleId IdType="pmc">PMC7516108</ArticleId><ArticleId IdType="pubmed">32107560</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Pike M, Merrill JT, et al. . Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2022. 10.1002/art.42391</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42391</ArticleId><ArticleId IdType="pmc">PMC10100399</ArticleId><ArticleId IdType="pubmed">36369798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:222&#x2013;31. 10.1016/S0140-6736(18)31363-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D, Matos A, Henriques C, et al. . Derivation and validation of the SLE disease activity score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 2019;78:365&#x2013;71. 10.1136/annrheumdis-2018-214502</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214502</ArticleId><ArticleId IdType="pubmed">30626657</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva L, Cunha AR, Jesus D, et al. . OP0293&#x2005;Optimizing a tool to identify lupus flares in daily clinical practice: SLE-DAS flare versus selena flare index. Ann Rheum Dis 2021;80:179. 10.1136/annrheumdis-2021-eular.748</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.748</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D, Larosa M, Henriques C, et al. . Systemic lupus erythematosus disease activity score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis 2021;80:1568&#x2013;74. 10.1136/annrheumdis-2021-220363</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220363</ArticleId><ArticleId IdType="pubmed">34407927</ArticleId></ArticleIdList></Reference><Reference><Citation>Assun&#xe7;&#xe3;o H, Jesus D, Larosa M, et al. . Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford) 2022;61:3309&#x2013;16. 10.1093/rheumatology/keab895</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab895</ArticleId><ArticleId IdType="pubmed">34864894</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, et al. . Development and validation of a novel evidence-based lupus multivariable outcome score for clinical trials. Arthritis Rheumatol 2018;70:1450&#x2013;8. 10.1002/art.40522</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40522</ArticleId><ArticleId IdType="pubmed">29648686</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly K, Eades L, Koelmeyer R, et al. . Towards a novel clinician-reported outcome measure for SLE &#x2013; outcomes of an international consensus process. Arthritis Rheumatol 2022;74.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>